KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

PLoS Medicine - Tập 2 Số 1 - Trang e17
William Pao1,2, Theresa Y. Wang2, Gregory J. Riely1, Vincent A. Miller1, Qiulu Pan3, Marc Ladanyi3, Maureen F. Zakowski3, Robert T. Heelan4, Mark G. Kris1, Harold Varmus2
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
2Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
3Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
4Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

Tóm tắt

Từ khóa


Tài liệu tham khảo

Lynch, 2004, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938

Paez, 2004, Science, 304, 1497, 10.1126/science.1099314

Pao, 2004, Proc Natl Acad Sci U S A, 101, 13306, 10.1073/pnas.0405220101

Stephens, 2004, Nature, 431, 525, 10.1038/431525b

Rodenhuis, 1988, Cancer Res, 48, 5738

Suzuki, 1990, Oncogene, 5, 1037

Rodenhuis, 1990, Amer Rev Resp Dis, 142, S27, 10.1164/ajrccm/142.6_Pt_2.S27

Gazdar, 2004, Trends Mol Med, 10, 481, 10.1016/j.molmed.2004.08.008

Ahrendt, 2001, Cancer, 92, 1525, 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H

Therasse, 2000, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205

Sordella, 2004, Science, 305, 1163, 10.1126/science.1101637

Rusch, 1992, J Thor Cardiovasc Surg, 104, 1465, 10.1016/S0022-5223(19)34644-6

Thông tin
Thông tin xuất bản

PLoS Medicine

Tập 2 Số 1

e17

Thông tin tác giả